IMpassion031: Results from a Phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

IMpassion031 is a global, phase III, multicentre, double-blind, randomised, placebo-controlled study in patients with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadjuvant atezolizumab or placebo with nab-paclitaxel followed by atezolizumab or placebo with dose-dense doxorubicin + cyclophosphamide. Here, we report the primary analysis of IMpassion031.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.